Artiva Biotherapeutics
June 16, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
Artiva (NASDAQ: ARTV) is a San Diego-based, clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers.
Artiva’s lead program, AlloNK®, is an off-the-shelf, natural killer (NK) cell therapy candidate designed to drive B-cell depletion in combination with monoclonal antibodies. AlloNK is currently in clinical trials for treatment of systemic lupus erythematosus and lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications including rheumatoid arthritis, certain forms of ANCA-vasculitis, and pemphigus vulgaris. AlloNK is also being developed in combination with Affimed’s acimtamig (AFM13) in relapsed/refractory CD30-positive lymphomas.
Company HQ City:
San Diego
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2019
Lead Product in Development:
AlloNK (AB-101)
CEO
Dr. Fred Aslan
Year Founded
2019
Development Phase of Lead Product
Phase I
Exchange
NASDAQ
Ticker
ARTV
When you expect your next catalyst update?
Initial data on autoimmune indications from at least one of our Phase 1/1b trial or basket IIT.
What is your next catalyst (value inflection) update?
1H 2025
Website
https://www.artivabio.com/
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}